

Brian Berman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2333417/publications.pdf>

Version: 2024-02-01

38
papers

1,236
citations

623574

14
h-index

414303

32
g-index

40
all docs

40
docs citations

40
times ranked

1471
citing authors

#	ARTICLE	IF	CITATIONS
1	Expert Recommendations on the Evaluation of Sunscreen Efficacy and the Beneficial Role of Non-filtering Ingredients. <i>Frontiers in Medicine</i> , 2022, 9, 790207.	1.2	11
2	A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 107-114.	1.1	3
3	Efficacy of aminolevulinic acid 20 % solution photodynamic therapy in the treatment of actinic keratoses on the upper extremities: A post hoc analysis of a phase 3, randomized, vehicle-controlled trial. <i>Photodiagnosis and Photodynamic Therapy</i> , 2020, 32, 102013.	1.3	8
4	Assessing keloid recurrence following surgical excision and radiation. <i>Burns and Trauma</i> , 2020, 8, tkaa031.	2.3	25
5	An overview of superficial radiation of surgical keloidectomy sites to reduce keloid recurrences. <i>Dermatological Reviews</i> , 2020, 1, 170-172.	0.3	0
6	Treating scars and laser resurfacing in 2021. <i>Dermatological Reviews</i> , 2020, 1, 153-153.	0.3	0
7	Efficacy and safety of ingenol disoxate gel in field treatment of actinic keratosis on full face, scalp or large area (250 cm ²) on the chest: results of four phase 3 randomized controlled trials. <i>Dermatology Online Journal</i> , 2020, 26, .	0.2	0
8	Safety, tolerability, and PK of topical calcitriol formulation for treatment of chemotherapy-induced alopecia (CIA) in patients receiving taxane-based regimen: Final results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11608-11608.	0.8	0
9	Efficacy Endpoints in Clinical Trials in Actinic Keratosis. <i>Dermatology and Therapy</i> , 2018, 8, 425-433.	1.4	9
10	Keloids and Hypertrophic Scars: Pathophysiology, Classification, and Treatment. <i>Dermatologic Surgery</i> , 2017, 43, S3-S18.	0.4	418
11	Integrating Skin Cancer-Related Technologies into Clinical Practice. <i>Dermatologic Clinics</i> , 2017, 35, 565-576.	1.0	10
12	A phase I safety study of topical calcitriol (BPM 31543) for the prevention of chemotherapy-induced alopecia (CIA).. <i>Journal of Clinical Oncology</i> , 2017, 35, e14064-e14064.	0.8	1
13	Updates on Keloidal Wound Healing. <i>Current Dermatology Reports</i> , 2016, 5, 252-259.	1.1	0
14	Topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA): Efficacy findings from a phase I safety study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2564-2564.	0.8	2
15	Objective Assessment of the Precision, Accuracy, and Reliability of a Measurement Method for Keloid Scar Volume (PARKS Study). <i>Dermatologic Surgery</i> , 2015, 41, 1274-1282.	0.4	7
16	Safety and tolerability of ingenol mebutate in the treatment of actinic keratosis. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1969-1978.	1.0	13
17	Safety and Efficacy of Oral <i>Polypodium leucotomos</i> Extract in Healthy Adult Subjects. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2015, 8, 19-23.	0.1	17
18	Assessment of local skin reactions with a sequential regimen of cryosurgery followed by ingenol mebutate gel, 0.015%, in patients with actinic keratosis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2014, 8, 1.	0.8	4

#	ARTICLE	IF	CITATIONS
19	A novel hydrogel scaffold for the prevention or reduction of the recurrence of keloid scars postsurgical excision. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 828-830.	0.6	13
20	Pathobiology of actinic keratosis: Ultraviolet-dependent keratinocyte proliferation. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, S10-S19.	0.6	115
21	Update on Keloid Management: Clinical and Basic Science Advances. <i>Advances in Wound Care</i> , 2012, 1, 200-206.	2.6	27
22	Pharmacotherapy of actinic keratosis: an update. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1847-1871.	0.9	28
23	New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2012, 5, 111.	0.8	53
24	The role of imiquimod 3.75% cream in the treatment of external genital warts. <i>Skin Therapy Letter</i> , 2012, 17, 5-7.	0.3	5
25	Exacerbation of facial acne vulgaris after consuming pure chocolate. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, e114-e115.	0.6	30
26	Biological Agents for Controlling Excessive Scarring. <i>American Journal of Clinical Dermatology</i> , 2010, 11, 31-34.	3.3	3
27	Pharmacotherapy of actinic keratosis. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 3015-3031.	0.9	26
28	Treatment of keloid scars post-shave excision with imiquimod 5% cream: A prospective, double-blind, placebo-controlled pilot study. <i>Journal of Drugs in Dermatology</i> , 2009, 8, 455-8.	0.4	34
29	Prevention and Management of Hypertrophic Scars and Keloids After Burns in Children. <i>Journal of Craniofacial Surgery</i> , 2008, 19, 989-1006.	0.3	119
30	Scientific rationale: combining imiquimod and surgical treatments for basal cell carcinomas. <i>Journal of Drugs in Dermatology</i> , 2008, 7, s3-6.	0.4	4
31	Evaluating the tolerability and efficacy of etanercept compared to triamcinolone acetonide for the intralesional treatment of keloids. <i>Journal of Drugs in Dermatology</i> , 2008, 7, 757-61.	0.4	17
32	A Review of the Biologic Effects, Clinical Efficacy, and Safety of Silicone Elastomer Sheeting for Hypertrophic and Keloid Scar Treatment and Management. <i>Dermatologic Surgery</i> , 2007, 33, 1291-1303.	0.4	158
33	Update on rosacea and oracea. <i>Drugs of Today</i> , 2007, 43, 27.	0.7	31
34	Mechanisms of action of new treatment modalities for actinic keratosis. <i>Journal of Drugs in Dermatology</i> , 2006, 5, 167-73.	0.4	13
35	Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel. <i>Journal of Family Practice</i> , 2006, 55, suppl 1-8.	0.2	14
36	Determination of the Area of Skin Capable of Being Covered by the Application of 250 mg of 5% Imiquimod Cream. <i>Dermatologic Surgery</i> , 2004, 30, 784-786.	0.4	9

#	ARTICLE	IF	CITATIONS
37	3. Successful Management of Viral Infections and Other Dermatoses with Imiquimod 5% Cream. Acta Dermato-Venereologica, 2003, 83, 12-17.	0.6	8
38	Actinic keratoses: The latest in therapy. Dermatological Reviews, 0, , .	0.3	0